Depomed, Inc.

NEWARK, Calif., June 11, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Wells Fargo Securities 2013 Healthcare Conference at the Intercontinental Hotel in Boston, MA. The presentation at the Wells Fargo conference is scheduled for 11:15 am EDT (8:15 am PDT) ... read more

NEWARK, Calif., May 31, 2013 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO), a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to the New Drug Application for SEFELSA, Depomed's investigational, oral, twice daily formulation of gabapentin( )to ... read more

NEWARK, Calif., May 28, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Jefferies 2013 Global Healthcare Conference at the Grand Hyatt in New York City. The presentation at the Jefferies conference is scheduled for 4:30 pm EDT (1:30 pm PDT) ... read more

NEWARK, Calif., May 16, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the UBS Global Healthcare Conference at the Sheraton New York Hotel in New York City. The presentation at the UBS conference is scheduled for 10 am EDT (7 am PDT) ... read more

NEWARK, Calif., May 8, 2013 /PRNewswire/ -- Depomed, Inc. (Nasdaq:DEPO) today reported financial results for the quarter ended March 31, 2013. First Quarter 2013 Update -- Total revenues of $26.2 million, an increase of 55% over first quarter 2012 ... read more

NEWARK, Calif., May 1, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first quarter fiscal year 2013 financial results after the market closes on Wednesday, May 8, 2013. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm ... read more

NEWARK, Calif., March 13, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Roth Capital Partners 25th Annual Growth Stock Conference at the Ritz-Carlton Hotel in Dana Point, California. The presentation at the Roth conference is scheduled for 11:30 am PDT (2:30 ... read more

NEWARK, Calif., March 4, 2013 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO), a specialty pharmaceutical company, announced today that the Reproductive Health Drugs Advisory Committee (RHDAC) of the U.S. Food and Drug Administration (FDA) voted 2-12 against approval for SEFELSA, Depomed's investigational, oral, twice daily formulation of gabapentin,( ... read more

NEWARK, Calif., March 4, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) announced that NASDAQ has halted trading of the company's common stock. The U.S. Food and Drug Administration's (FDA) Reproductive Health Drugs Advisory Committee is meeting this morning to discuss the company's New Drug Application (NDA) ... read more

NEWARK, Calif., Feb. 26, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Cowen and Company 33rd Annual Health Care Conference at the Boston Marriott Copley Place Hotel in Boston. The presentation at the Cowen conference is scheduled for 10:00 am EST ... read more

NEWARK, Calif., Feb. 20, 2013 /PRNewswire/ -- Depomed, Inc. (Nasdaq:DEPO) today reported financial results for the quarter and twelve months ended December 31, 2012. 2012 Financial and Business Highlights -- Fourth Quarter 2012 Highlights: -- Total revenues of ... read more

NEWARK, Calif., Feb. 13, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2012 financial results after the market closes on Wednesday, February 20, 2013. The Company will host a conference call beginning at 4:30 pm Eastern time, 1:30 pm ... read more

NEWARK, Calif., Dec. 26, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that its lawsuits against two filers of Abbreviated New Drug Applications (ANDAs) for Gralise(®) (gabapentin) have been dismissed. Watson Laboratories has withdrawn its Gralise ANDA. Par Pharmaceutical has amended its Gralise ANDA and ... read more

MENLO PARK, CA -- (Marketwire) -- 02/08/11 -- Depomed, Inc. (NASDAQ: DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the 13th Annual BIO CEO & Investor Conference in New York City on February 15, 2011 at 8:30 am EST. The ... read more

MENLO PARK, CA -- (Marketwire) -- 02/07/11 -- Depomed, Inc. (NASDAQ: DEPO) today announced that in its second Phase 1 pharmacokinetic-pharmacodynamic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric-retentive, extended-release formulation of levodopa/carbidopa, maintained therapeutic blood levels of levodopa over 24 hours in a twice-daily formulation. Two distinct ... read more

MENLO PARK, CA -- (Marketwire) -- 11/17/10 -- Depomed, Inc. (NASDAQ: DEPO) today announced that it ranked number 93 on Technology Fast 500TM, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the period ... read more

MENLO PARK, CA -- (Marketwire) -- 11/17/10 -- Depomed, Inc. (NASDAQ: DEPO) today announced that it ranked number 93 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of ... read more

MENLO PARK, CA -- (Marketwire) -- 11/02/10 -- MENLO PARK, Calif. - November 2, 2010 - Depomed, Inc. (NASDAQ: DEPO) announced today that it has been awarded two cash grants totaling approximately $489,000 under the U.S. Government's Qualifying Therapeutic Discovery Project ("QTDP") program. The QTDP program was part of the Patient Protection and Affordable Care Act signed into ... read more

MENLO PARK, CA -- (Marketwire) -- 11/02/10 -- Depomed, Inc. (NASDAQ: DEPO) announced today that it has been awarded two cash grants totaling approximately $489,000 under the U.S. Government's Qualifying Therapeutic Discovery Project ("QTDP") program. The QTDP program was part of the Patient Protection and Affordable Care Act signed ... read more

MENLO PARK, CA -- (Marketwire) -- 11/01/10 -- Depomed, Inc. (NASDAQ: DEPO) today reported financial results for the third quarter ended September 30, 2010. Revenue for the three months ended September 30, 2010 was $20.1 million and included recognition of $6.0 million in milestones: * a $5.0 million milestone from Janssen ... read more